Skip to main content
Top
Published in: American Journal of Clinical Dermatology 5/2002

01-08-2002 | Review Article

Adverse Cutaneous Reactions to Antidepressants

Authors: Dr Julia K. Warnock, David W. Morris

Published in: American Journal of Clinical Dermatology | Issue 5/2002

Login to get access

Abstract

Antidepressants are among the most widely prescribed medications in the United States. Adverse cutaneous drug reactions (ACDRs) associated with drugs are common, with possibly higher rates associated with psychotropic medications. While the vast majority of ACDRs are benign and easily treated, serious and life-threatening ACDRs, such as those associated with antidepressants, do rarely occur. ACDRs to antidepressants are diagnosed primarily on the basis of the patient’s history. A clinician who is aware of these common and potentially serious adverse events will help avoid their continuation or recurrence. There are certain characteristics that place an individual at higher risk for an ACDR such as female gender, increasing age, African- American ethnicity, use of multiple medications and presence of a serious illness.
If a cutaneous reaction occurs in an outpatient setting, it is advisable to discontinue the offending antidepressant and substitute it with one from another class. Treatment of the ACDR should be symptomatic if the patient shows no other significant signs of reaction. If other signs are present, however, a dermatology consultation should be obtained. Since the diagnosis of ACDRs is often tentative, and the exanthema is likely to be benign, the physician treating a patient with a mood or anxiety disorder must weigh the risk of developing these potential problems against the possibility of relapse of the psychiatric disorder should the medication be discontinued.
Literature
1.
go back to reference Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the US: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan; 51 (1): 8–19PubMedCrossRef Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the US: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan; 51 (1): 8–19PubMedCrossRef
2.
go back to reference Narrow WE. One year prevalence of depressive disorders among adults 18 and over in the US: NIMH ECA prospective data. Population estimates based upon US Census estimated residential population age 10 and over on July 1 1998 [data on file] Narrow WE. One year prevalence of depressive disorders among adults 18 and over in the US: NIMH ECA prospective data. Population estimates based upon US Census estimated residential population age 10 and over on July 1 1998 [data on file]
3.
go back to reference Later AW. The top 200 drugs of 1999 [online]. Available from URL:http://www.parmacytimes.com/top200a.html [Accessed 2002 May 12] Later AW. The top 200 drugs of 1999 [online]. Available from URL:http://​www.​parmacytimes.​com/​top200a.​html [Accessed 2002 May 12]
4.
go back to reference Drake L.A., Dinehart S.M., Farmer E.R., et al. Guidelines of care for cutaneous adverse drug reactions: American Academy of Dermatology. J Am Acad Dermatol 1996 Sep; 35 (3 Pt 1): 458–461PubMedCrossRef Drake L.A., Dinehart S.M., Farmer E.R., et al. Guidelines of care for cutaneous adverse drug reactions: American Academy of Dermatology. J Am Acad Dermatol 1996 Sep; 35 (3 Pt 1): 458–461PubMedCrossRef
5.
go back to reference Litvak R., Kaelbling R. Dermatological side effects with psychotropics. Dis Nerv Syst 1972 May; 33 (5): 309–311PubMed Litvak R., Kaelbling R. Dermatological side effects with psychotropics. Dis Nerv Syst 1972 May; 33 (5): 309–311PubMed
6.
go back to reference Bigby M., Jick S., Jick H., et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986 Dec; 256 (24): 3358–3363PubMedCrossRef Bigby M., Jick S., Jick H., et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986 Dec; 256 (24): 3358–3363PubMedCrossRef
7.
go back to reference Alanko K., Stubb S., Kauppinen K. Cutaneous drug reactions, clinical types and causative agents: a five-year study of in-patients (1981–1985). Acta Derm Venereol (Stockh) 1989; 69: 223–226 Alanko K., Stubb S., Kauppinen K. Cutaneous drug reactions, clinical types and causative agents: a five-year study of in-patients (1981–1985). Acta Derm Venereol (Stockh) 1989; 69: 223–226
8.
go back to reference Stern R.S., Steinberg L.A. Epidemiology of adverse cutaneous reactions to drugs. Dermatol Clin 1995 Jul; 13 (3): 681–688PubMed Stern R.S., Steinberg L.A. Epidemiology of adverse cutaneous reactions to drugs. Dermatol Clin 1995 Jul; 13 (3): 681–688PubMed
9.
go back to reference Fitzpatrick T.B., Johnson R.A., Wolff K., et al. Color atlas and synopsis of clinical dermatology: common and serious diseases. 4th ed. New York: McGraw- Hill, 2001 Fitzpatrick T.B., Johnson R.A., Wolff K., et al. Color atlas and synopsis of clinical dermatology: common and serious diseases. 4th ed. New York: McGraw- Hill, 2001
10.
go back to reference Perry P.J., Alexander B., Liskow B.I. Psychotropic drug handbook. 7th ed. Washington, DC: American Psychiatric Press, 1997 Perry P.J., Alexander B., Liskow B.I. Psychotropic drug handbook. 7th ed. Washington, DC: American Psychiatric Press, 1997
11.
go back to reference Medical Economics. Physician’s desk reference. 55th ed. Montvale (NJ): Medical Economics, 2001 Medical Economics. Physician’s desk reference. 55th ed. Montvale (NJ): Medical Economics, 2001
12.
go back to reference Medical Economics. Physician’s desk reference. 48th ed. Montvale (NJ): Medical Economics, 1994 Medical Economics. Physician’s desk reference. 48th ed. Montvale (NJ): Medical Economics, 1994
13.
go back to reference Steele T.E., Ashby J. Desipramine-related slate-gray skin pigmentation [letter]. J Clin Psychopharmacol 1993 Feb; 13 (1): 76–77PubMedCrossRef Steele T.E., Ashby J. Desipramine-related slate-gray skin pigmentation [letter]. J Clin Psychopharmacol 1993 Feb; 13 (1): 76–77PubMedCrossRef
14.
go back to reference Warnock J.K., Sieg K., Willsie D., et al. Drug-related alopecia in patients treated with tricyclic antidepressants. J Nerv Ment Dis 1991 Jul; 179 (7): 441–442PubMedCrossRef Warnock J.K., Sieg K., Willsie D., et al. Drug-related alopecia in patients treated with tricyclic antidepressants. J Nerv Ment Dis 1991 Jul; 179 (7): 441–442PubMedCrossRef
15.
go back to reference Narurkar V., Smoller B.R., Hu C.H., et al. Desipramine-induced blue-gray photosensitive pigmentation. Arch Dermatol 1993 Apr; 129 (4): 474–476PubMedCrossRef Narurkar V., Smoller B.R., Hu C.H., et al. Desipramine-induced blue-gray photosensitive pigmentation. Arch Dermatol 1993 Apr; 129 (4): 474–476PubMedCrossRef
16.
go back to reference Panuska J.R., King T.R., Korenblat P.E., et al. Hypersensitivity reaction to desipramine. J Allergy Clin Immunol 1987 Jul; 80 (1): 18–23PubMedCrossRef Panuska J.R., King T.R., Korenblat P.E., et al. Hypersensitivity reaction to desipramine. J Allergy Clin Immunol 1987 Jul; 80 (1): 18–23PubMedCrossRef
17.
go back to reference Basler R.S., Goetz C.S. Synergism of minocycline and amitriptyline in cutaneous hyperpigmentation [letter]. J Am Acad Dermatol 1985 Mar; 12 (3): 577PubMedCrossRef Basler R.S., Goetz C.S. Synergism of minocycline and amitriptyline in cutaneous hyperpigmentation [letter]. J Am Acad Dermatol 1985 Mar; 12 (3): 577PubMedCrossRef
18.
go back to reference Milionis H.J., Skopelitou A., Elisaf M.S. Hypersensitivity syndrome caused by amitriptyline administration. Postgrad Med J 2000 Jun; 76 (896): 361–363PubMedCrossRef Milionis H.J., Skopelitou A., Elisaf M.S. Hypersensitivity syndrome caused by amitriptyline administration. Postgrad Med J 2000 Jun; 76 (896): 361–363PubMedCrossRef
19.
go back to reference Tunca Z., Tunca M.I., Dilsiz A., et al. Clomipramine-induced pseudocyanotic pigmentation. Am J Psychiatry 1989 Apr; 146 (4): 552–553PubMed Tunca Z., Tunca M.I., Dilsiz A., et al. Clomipramine-induced pseudocyanotic pigmentation. Am J Psychiatry 1989 Apr; 146 (4): 552–553PubMed
20.
go back to reference Baral J., Deakins S. Imipramine-induced alopecia areata-like lesions [letter]. Int J Dermatol 1987 Apr; 26 (3): 198PubMedCrossRef Baral J., Deakins S. Imipramine-induced alopecia areata-like lesions [letter]. Int J Dermatol 1987 Apr; 26 (3): 198PubMedCrossRef
21.
go back to reference Ming M.E., Bhawan J., Stefanato C.M., et al. Imipramine-induced hyperpigmentation: four cases and a review of the literature. J Am Acad Dermatol 1999 Feb; 40 (2 Pt 1): 159–166PubMedCrossRef Ming M.E., Bhawan J., Stefanato C.M., et al. Imipramine-induced hyperpigmentation: four cases and a review of the literature. J Am Acad Dermatol 1999 Feb; 40 (2 Pt 1): 159–166PubMedCrossRef
22.
go back to reference Hashimoto K., Joselow S.A., Tye M.J. Imipramine hyperpigmentation: a slate-gray discoloration caused by long-term imipramine administration. J Am Acad Dermatol 1991 Aug; 25 (2 Pt 2): 357–361PubMedCrossRef Hashimoto K., Joselow S.A., Tye M.J. Imipramine hyperpigmentation: a slate-gray discoloration caused by long-term imipramine administration. J Am Acad Dermatol 1991 Aug; 25 (2 Pt 2): 357–361PubMedCrossRef
23.
go back to reference Atkin D.H., Fitzpatrick R.E. Laser treatment of imipramine-induced hyperpigmentation. J Am Acad Dermatol 2000 Jul; 43 (1 Pt 1): 77–80PubMedCrossRef Atkin D.H., Fitzpatrick R.E. Laser treatment of imipramine-induced hyperpigmentation. J Am Acad Dermatol 2000 Jul; 43 (1 Pt 1): 77–80PubMedCrossRef
24.
go back to reference Kimyai-Asadi A., Harris J.C., Nousari H.C. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999 Oct; 60 (10): 714–725PubMedCrossRef Kimyai-Asadi A., Harris J.C., Nousari H.C. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999 Oct; 60 (10): 714–725PubMedCrossRef
25.
go back to reference Knowles S.R., Shapiro L.E., Shear N.H. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999 Dec; 21 (6): 489–501PubMedCrossRef Knowles S.R., Shapiro L.E., Shear N.H. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999 Dec; 21 (6): 489–501PubMedCrossRef
26.
go back to reference Camisa C., Grines C. Amoxapine: a cause of toxic epidermal necrolysis [letter]? Arch Dermatol 1983 Sep; 119 (9): 709–710PubMedCrossRef Camisa C., Grines C. Amoxapine: a cause of toxic epidermal necrolysis [letter]? Arch Dermatol 1983 Sep; 119 (9): 709–710PubMedCrossRef
27.
go back to reference Gaufberg E., Ellison J.M. Photosensitivity reaction to fluoxetine [letter]. J Clin Psychiatry 1995 Oct; 56 (10): 486PubMed Gaufberg E., Ellison J.M. Photosensitivity reaction to fluoxetine [letter]. J Clin Psychiatry 1995 Oct; 56 (10): 486PubMed
28.
go back to reference Gillet-Terver M.N., Modiano P., Trechot P., et al. Fluvoxamine photosensitivity [letter]. Australas J Dermatol 1996 Feb; 37 (1): 62PubMedCrossRef Gillet-Terver M.N., Modiano P., Trechot P., et al. Fluvoxamine photosensitivity [letter]. Australas J Dermatol 1996 Feb; 37 (1): 62PubMedCrossRef
29.
go back to reference Wernicke J.F. The side effect profile and safety of fluoxetine. J Clin Psychiarty 1985 Mar; 46 (3 Pt 2): 59–67 Wernicke J.F. The side effect profile and safety of fluoxetine. J Clin Psychiarty 1985 Mar; 46 (3 Pt 2): 59–67
30.
go back to reference Hemlock C., Rosenthal J.S., Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 1992 Feb; 26 (2): 211–212PubMed Hemlock C., Rosenthal J.S., Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 1992 Feb; 26 (2): 211–212PubMed
31.
go back to reference Cooper G.L. The safety of fluoxetine: an update. Br J Psychiatry 1988; 3: 77–86 Cooper G.L. The safety of fluoxetine: an update. Br J Psychiatry 1988; 3: 77–86
32.
go back to reference Miller L.G., Bowman R.C., Mann D., et al. A case of fluoxetine-induced serum sickness. Am J Psychiatry 1989 Dec; 146 (12): 1616–1617PubMed Miller L.G., Bowman R.C., Mann D., et al. A case of fluoxetine-induced serum sickness. Am J Psychiatry 1989 Dec; 146 (12): 1616–1617PubMed
33.
go back to reference Lineberry T.W., Peters G.E., Bostwick J.M. Bupropion-induced erythema multiforme. Mayo Clin Proc 2001 Jun; 76 (6): 664–666PubMed Lineberry T.W., Peters G.E., Bostwick J.M. Bupropion-induced erythema multiforme. Mayo Clin Proc 2001 Jun; 76 (6): 664–666PubMed
34.
go back to reference Preskorn S.H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56 (6 Suppl.): 12–21PubMed Preskorn S.H. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995; 56 (6 Suppl.): 12–21PubMed
35.
go back to reference McCollom R.A., Elbe D.H., Ritchie A.H. Bupropion-induced serum sickness-like reaction. Ann Pharmacother 2000 Apr; 34 (4): 471–473PubMedCrossRef McCollom R.A., Elbe D.H., Ritchie A.H. Bupropion-induced serum sickness-like reaction. Ann Pharmacother 2000 Apr; 34 (4): 471–473PubMedCrossRef
36.
go back to reference Peloso P.M., Baillie C. Serum sickness-like reaction to bupropion [letter]. JAMA 1999 Nov; 282 (19): 1817PubMedCrossRef Peloso P.M., Baillie C. Serum sickness-like reaction to bupropion [letter]. JAMA 1999 Nov; 282 (19): 1817PubMedCrossRef
37.
go back to reference Yolles J.C., Armenta W.A., Alao A.O. Serum sickness induced by bupropion. Ann Pharmacother 1999 Sep; 33 (9): 931–933PubMedCrossRef Yolles J.C., Armenta W.A., Alao A.O. Serum sickness induced by bupropion. Ann Pharmacother 1999 Sep; 33 (9): 931–933PubMedCrossRef
38.
go back to reference Tripathi A., Greenberger P.A. Bupropion hydrochloride induced serum sicknesslike reaction. Ann Allergy Asthma Immunol 1999 Aug; 83 (2): 165–166PubMedCrossRef Tripathi A., Greenberger P.A. Bupropion hydrochloride induced serum sicknesslike reaction. Ann Allergy Asthma Immunol 1999 Aug; 83 (2): 165–166PubMedCrossRef
39.
go back to reference Barth J.H., Baker H. Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br J Dermatol 1986 Nov; 115 (5): 629–630PubMedCrossRef Barth J.H., Baker H. Generalized pustular psoriasis precipitated by trazodone in the treatment of depression. Br J Dermatol 1986 Nov; 115 (5): 629–630PubMedCrossRef
40.
go back to reference Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994 Nov 10; 331 (19): 1272–1285PubMedCrossRef Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994 Nov 10; 331 (19): 1272–1285PubMedCrossRef
41.
go back to reference Ponte C.D. Maprotiline-induced acne [letter]. Am J Psychiatry 1982 Jan; 139 (1): 141PubMed Ponte C.D. Maprotiline-induced acne [letter]. Am J Psychiatry 1982 Jan; 139 (1): 141PubMed
42.
go back to reference Oakley A.M., Hodge L. Cutaneous vasculitis from maprotiline. Aust N Z J Med 1985 Apr; 15 (2): 256–257PubMedCrossRef Oakley A.M., Hodge L. Cutaneous vasculitis from maprotiline. Aust N Z J Med 1985 Apr; 15 (2): 256–257PubMedCrossRef
43.
go back to reference Mann S.C., Walker M.M., Messenger G.G., et al. Leukocytoclastic vasculitis secondary to trazodone treatment. J Am Acad Dermatol 1984 Apr; 10 (4): 669–670PubMedCrossRef Mann S.C., Walker M.M., Messenger G.G., et al. Leukocytoclastic vasculitis secondary to trazodone treatment. J Am Acad Dermatol 1984 Apr; 10 (4): 669–670PubMedCrossRef
44.
go back to reference Powell Jr W.J., Koch-Weser J., Williams R.A. Lethal hepatic necrosis after therapy with imipramine and desipramine. JAMA 1968 Oct 14; 206 (3): 642–645PubMedCrossRef Powell Jr W.J., Koch-Weser J., Williams R.A. Lethal hepatic necrosis after therapy with imipramine and desipramine. JAMA 1968 Oct 14; 206 (3): 642–645PubMedCrossRef
45.
go back to reference Taniguchi S., Hamada T. Photosensitivity and thrombocytopenia due to amitriptyline. Am J Hematol 1996 Sep; 53 (1): 49–50PubMedCrossRef Taniguchi S., Hamada T. Photosensitivity and thrombocytopenia due to amitriptyline. Am J Hematol 1996 Sep; 53 (1): 49–50PubMedCrossRef
46.
go back to reference Kochevar I.E. Possible mechanisms of toxicity due to photochemical products of protriptyline. Toxicol Appl Pharmacol 1980 Jun 30; 54 (2): 258–264PubMedCrossRef Kochevar I.E. Possible mechanisms of toxicity due to photochemical products of protriptyline. Toxicol Appl Pharmacol 1980 Jun 30; 54 (2): 258–264PubMedCrossRef
47.
go back to reference Ljunggren D., Bojs G. A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features. Contact Dermatitis 1991 Apr; 24 (4): 259–265PubMedCrossRef Ljunggren D., Bojs G. A case of photosensitivity and contact allergy to systemic tricyclic drugs, with unusual features. Contact Dermatitis 1991 Apr; 24 (4): 259–265PubMedCrossRef
48.
go back to reference Case J.D., Yusk J.W., Callen J.P. Photosensitive reaction to phenelzine: a case report. Photodermatology 1988 Apr; 5 (2): 101–102PubMed Case J.D., Yusk J.W., Callen J.P. Photosensitive reaction to phenelzine: a case report. Photodermatology 1988 Apr; 5 (2): 101–102PubMed
49.
50.
go back to reference Grupta S., Major L.F. Hair loss associated with fluoxetine. Br J Dermatol 1991 Nov; 159: 737–738 Grupta S., Major L.F. Hair loss associated with fluoxetine. Br J Dermatol 1991 Nov; 159: 737–738
51.
go back to reference Seifritz E., Hatzinger M., Muller M.J., et al. Hair loss associated with fluoxetine but not with citalopram [letter]. Can J Psychiatry 1995 Aug; 40 (6): 362PubMed Seifritz E., Hatzinger M., Muller M.J., et al. Hair loss associated with fluoxetine but not with citalopram [letter]. Can J Psychiatry 1995 Aug; 40 (6): 362PubMed
52.
go back to reference Mareth T.R. Hair loss associated with fluoxetine use in two family members [letter]. J Clin Psychiatry 1994 Apr; 55 (4): 163PubMed Mareth T.R. Hair loss associated with fluoxetine use in two family members [letter]. J Clin Psychiatry 1994 Apr; 55 (4): 163PubMed
53.
go back to reference Ananth J., Elmishaugh A. Hair loss associated with fluoxetine treatment [letter]. Can J Psychiatry 1991; 36: 621PubMed Ananth J., Elmishaugh A. Hair loss associated with fluoxetine treatment [letter]. Can J Psychiatry 1991; 36: 621PubMed
54.
go back to reference Jenike M.A. Severe hair loss associated with fluoxetine use [letter]. Am J Psychiatry 1991 Mar; 148 (3): 392PubMed Jenike M.A. Severe hair loss associated with fluoxetine use [letter]. Am J Psychiatry 1991 Mar; 148 (3): 392PubMed
55.
go back to reference Bourgeois J.A. Two cases of hair loss after sertraline use. J Clin Psychopharmacol 1996 Feb; 16 (1): 91–92PubMedCrossRef Bourgeois J.A. Two cases of hair loss after sertraline use. J Clin Psychopharmacol 1996 Feb; 16 (1): 91–92PubMedCrossRef
56.
go back to reference Bhatara V.S., Gupta S., Freeman J.W. Fluoxetine associated paresthesias and alopecia in a woman who tolerated sertraline [letter]. J Clin Psychiatry 1996 May; 57 (5): 227PubMed Bhatara V.S., Gupta S., Freeman J.W. Fluoxetine associated paresthesias and alopecia in a woman who tolerated sertraline [letter]. J Clin Psychiatry 1996 May; 57 (5): 227PubMed
57.
go back to reference Parameshwar E. Hair loss associated with fluvoxamine use. Am J Psychiatry 1996 Apr; 153 (4): 581–582PubMed Parameshwar E. Hair loss associated with fluvoxamine use. Am J Psychiatry 1996 Apr; 153 (4): 581–582PubMed
58.
go back to reference Biederman J., Gonzalez E., Bronstein B., et al. Desipramine and cutaneous reactions in pediatric outpatients. J Clin Psychiatry 1988 May; 49 (5): 178–183PubMed Biederman J., Gonzalez E., Bronstein B., et al. Desipramine and cutaneous reactions in pediatric outpatients. J Clin Psychiatry 1988 May; 49 (5): 178–183PubMed
59.
go back to reference Popper C.W. Antidepressants in the treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry 1997; 58 (14 Suppl.): 14–29PubMed Popper C.W. Antidepressants in the treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry 1997; 58 (14 Suppl.): 14–29PubMed
60.
go back to reference McCollom R.A., Elbe D.H., Ritchie A.H. Bupropion-induced serum sickness-like reaction. Ann Pharmacother 2000 Apr; 34 (4): 471–473PubMedCrossRef McCollom R.A., Elbe D.H., Ritchie A.H. Bupropion-induced serum sickness-like reaction. Ann Pharmacother 2000 Apr; 34 (4): 471–473PubMedCrossRef
61.
go back to reference Doogan D.P. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991 Dec; 6 (2 Suppl.): 47–56PubMedCrossRef Doogan D.P. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991 Dec; 6 (2 Suppl.): 47–56PubMedCrossRef
62.
go back to reference Saraf K.R., Klein D.F., Gittelman-Klein R., et al. Imipramine side effects in children. Psychopharmacologia 1974 Jul 11; 37 (3): 265–274PubMedCrossRef Saraf K.R., Klein D.F., Gittelman-Klein R., et al. Imipramine side effects in children. Psychopharmacologia 1974 Jul 11; 37 (3): 265–274PubMedCrossRef
63.
go back to reference Schulterbrandt J.G., Raskin A., Reatig N. True and apparent side effects in a controlled trial of chlorpromazine and imipramine in depression. Psychopharmacologia 1974; 38 (4): 303–317PubMedCrossRef Schulterbrandt J.G., Raskin A., Reatig N. True and apparent side effects in a controlled trial of chlorpromazine and imipramine in depression. Psychopharmacologia 1974; 38 (4): 303–317PubMedCrossRef
64.
go back to reference Faltus F., Geerling F.C. A controlled double-blind study comparing binedaline and imipramine in the treatment of endogenous depression. Neuropsychobiology 1984; 12 (1): 34–38PubMedCrossRef Faltus F., Geerling F.C. A controlled double-blind study comparing binedaline and imipramine in the treatment of endogenous depression. Neuropsychobiology 1984; 12 (1): 34–38PubMedCrossRef
65.
go back to reference Butterworth A.T. Depression associated with alcohol withdrawal: Imipramine therapy compared with placebo. Q J Stud Alcohol 1971 Jun; 32 (2): 343–348PubMed Butterworth A.T. Depression associated with alcohol withdrawal: Imipramine therapy compared with placebo. Q J Stud Alcohol 1971 Jun; 32 (2): 343–348PubMed
66.
go back to reference Forrest W. A comparison between daily and nightly dose regimen of amitriptyline and maprotiline (Ludiomil) in the treatment of reactive depression in general practice. J Int Med Res 1975; 3 (2): 120–125 Forrest W. A comparison between daily and nightly dose regimen of amitriptyline and maprotiline (Ludiomil) in the treatment of reactive depression in general practice. J Int Med Res 1975; 3 (2): 120–125
67.
go back to reference Joffe R.T., Richter M.A. Allergic skin eruption with desipramine treatment. Can J Psychiatry 1987 Nov; 32 (8): 695–696PubMed Joffe R.T., Richter M.A. Allergic skin eruption with desipramine treatment. Can J Psychiatry 1987 Nov; 32 (8): 695–696PubMed
68.
go back to reference Cohen L.E. Drug eruption secondary to trazodone [letter]. J Am Acad Dermatol 1984 Sep; 11 (3): 526–527PubMedCrossRef Cohen L.E. Drug eruption secondary to trazodone [letter]. J Am Acad Dermatol 1984 Sep; 11 (3): 526–527PubMedCrossRef
69.
go back to reference Trapp G.A., Handorf C.R., Larach V. Trazodone in the treatment of depressed inpatients. Psychopharmacol Bull 1979 Jul; 15 (3): 25–27PubMed Trapp G.A., Handorf C.R., Larach V. Trazodone in the treatment of depressed inpatients. Psychopharmacol Bull 1979 Jul; 15 (3): 25–27PubMed
70.
go back to reference Bartholini E. Once daily dosage with maprotiline (Ludiomil). J Int Med Res 1975; 3 Suppl. 2: 101–108 Bartholini E. Once daily dosage with maprotiline (Ludiomil). J Int Med Res 1975; 3 Suppl. 2: 101–108
71.
go back to reference Molnar G. Maprotiline: a double-blind study of a new tetracyclic antidepressant in severe depression. Can Psychiatr Assoc J 1977 Feb; 22 (1): 19–23PubMed Molnar G. Maprotiline: a double-blind study of a new tetracyclic antidepressant in severe depression. Can Psychiatr Assoc J 1977 Feb; 22 (1): 19–23PubMed
72.
go back to reference Trick K.L. Double-blind comparison of maprotiline with amitriptyline in the treatment of depressive illness. Int Pharmacopsychiatry 1975; 10 (4): 193–198PubMed Trick K.L. Double-blind comparison of maprotiline with amitriptyline in the treatment of depressive illness. Int Pharmacopsychiatry 1975; 10 (4): 193–198PubMed
73.
go back to reference Information on adverse reactions to drugs. Lancet 1973 Feb 10; I (7798): 302-3 Information on adverse reactions to drugs. Lancet 1973 Feb 10; I (7798): 302-3
74.
go back to reference Almeyda J. Cutaneous reactions to imipramine and chlordiazepoxide. Br J Dermatol 1971 Mar; 84 (5): 298–300PubMedCrossRef Almeyda J. Cutaneous reactions to imipramine and chlordiazepoxide. Br J Dermatol 1971 Mar; 84 (5): 298–300PubMedCrossRef
75.
go back to reference Johnson N.M., Copeland G.P., Clarke S.W. Severe neutropenia and urticaria with antidepressant therapy [letter]. Lancet 1976 Dec 18; II (7999): 1357CrossRef Johnson N.M., Copeland G.P., Clarke S.W. Severe neutropenia and urticaria with antidepressant therapy [letter]. Lancet 1976 Dec 18; II (7999): 1357CrossRef
76.
go back to reference Fabre Jr L.F., Feighner J.P. Long-term therapy for depression with trazodone. J Clin Psychiatry 1983 Jan; 44 (1): 17–21PubMed Fabre Jr L.F., Feighner J.P. Long-term therapy for depression with trazodone. J Clin Psychiatry 1983 Jan; 44 (1): 17–21PubMed
77.
go back to reference Fisher S., Bryant S.G., Kent T.A. Postmarketing surveillance by patient self-monitoring: trazodone versus fluoxetine. J Clin Psychopharmacol 1993 Aug; 13 (4): 235–242PubMedCrossRef Fisher S., Bryant S.G., Kent T.A. Postmarketing surveillance by patient self-monitoring: trazodone versus fluoxetine. J Clin Psychopharmacol 1993 Aug; 13 (4): 235–242PubMedCrossRef
78.
go back to reference Leznoff A., Binkley K.E., Joffee R.T., et al. Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients. J Clin Psychopharmacol 1992 Oct; 12 (5): 355–357PubMedCrossRef Leznoff A., Binkley K.E., Joffee R.T., et al. Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients. J Clin Psychopharmacol 1992 Oct; 12 (5): 355–357PubMedCrossRef
79.
go back to reference Korkij W., Soltani K. Fixed drug eruption: a brief review. Arch Dermatol 1984 Apr; 120 (4): 520–524PubMedCrossRef Korkij W., Soltani K. Fixed drug eruption: a brief review. Arch Dermatol 1984 Apr; 120 (4): 520–524PubMedCrossRef
80.
go back to reference Harth Y., Rapoport M. Photosensitivity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996 Apr; 14 (4): 252–259PubMedCrossRef Harth Y., Rapoport M. Photosensitivity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996 Apr; 14 (4): 252–259PubMedCrossRef
81.
go back to reference Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996 Jul; 14 (3): 503–508PubMedCrossRef Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996 Jul; 14 (3): 503–508PubMedCrossRef
82.
go back to reference Stroud J.D. Drug-induced alopecia. Semin Dermatol 1985; 4: 29–34 Stroud J.D. Drug-induced alopecia. Semin Dermatol 1985; 4: 29–34
83.
go back to reference Warnock J.K. Psychotropic medication and drug-related alopecia. Psychosomatics 1991; 32 (2): 149–152PubMedCrossRef Warnock J.K. Psychotropic medication and drug-related alopecia. Psychosomatics 1991; 32 (2): 149–152PubMedCrossRef
84.
go back to reference Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 Oct; 282 (5388): 490–493PubMedCrossRef Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998 Oct; 282 (5388): 490–493PubMedCrossRef
85.
go back to reference deShazo R.D., Kemp S.F. Allergic reactions to drugs and biologic agents. JAMA 1997 Dec 10; 278 (22): 1895–1906PubMedCrossRef deShazo R.D., Kemp S.F. Allergic reactions to drugs and biologic agents. JAMA 1997 Dec 10; 278 (22): 1895–1906PubMedCrossRef
86.
go back to reference Manders S.M. Serious and life-threatening drug eruptions. Am Fam Physician 1995 Jun; 51 (8): 1865–1872PubMed Manders S.M. Serious and life-threatening drug eruptions. Am Fam Physician 1995 Jun; 51 (8): 1865–1872PubMed
87.
go back to reference MacMorran W.S., Krahn L.E. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997 Sep-Oct; 38 (5): 413–422PubMedCrossRef MacMorran W.S., Krahn L.E. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997 Sep-Oct; 38 (5): 413–422PubMedCrossRef
88.
go back to reference Warnock J.K., Knesevich J.W. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988 Apr; 145 (4): 425–430PubMed Warnock J.K., Knesevich J.W. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988 Apr; 145 (4): 425–430PubMed
Metadata
Title
Adverse Cutaneous Reactions to Antidepressants
Authors
Dr Julia K. Warnock
David W. Morris
Publication date
01-08-2002
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 5/2002
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200203050-00005

Other articles of this Issue 5/2002

American Journal of Clinical Dermatology 5/2002 Go to the issue

Leading Article

Self-Tanning Lotions

Current Opinion

Vitiligo